Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Common Stock Issued
Cash raised by issuing new shares.
Tenax Therapeutics, Inc.NASDAQ: TENX
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued growth accelerates
Q1 FY2026 common stock issued of $30.5M rose 29.4% year over year, ahead of the -60.8% change in trailing-twelve-month common stock issued. Sequentially, it rose 162.7% from the prior quarter. Over 3 fiscal years it compounded at +69.3% a year.
Context
- Common stock issued increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +29.4% holds above the trailing-twelve-month pace of -60.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 38.51M USD
- Year-over-year change
- -61.6%
- 4-year CAGR
- +43.1%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.51M | -61.6% |
| FY2024 | 2024-12-31 | 100.37M | +607.2% |
| FY2023 | 2023-12-31 | 14.19M | +79.0% |
| FY2022 | 2022-12-31 | 7.93M | -13.7% |
| FY2021 | 2021-12-31 | 9.19M | — |
Common Stock Issued vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's LTM Mar 2026 common stock issued of $45.45M is the 4th largest of the 7 companies compared; the peer median is $43.72M.
- Its year-over-year change of -60.8% is the 4th highest of 5, against a peer median of +21200.1%.
- Over three fiscal years its annual growth of +69.3% compares with a peer median of +13.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $351.06M | +11702097000.0% | +180.1% | — | |
| LTM Jun 2026 | $85.9M | — | — | — | |
| LTM Mar 2026 | $50.06M | +26.3% | +23.0% | 134.7% | |
| LTM Mar 2026 | $45.45M | -60.8% | +69.3% | — | |
| LTM Mar 2026 | $37.38M | +42373.9% | -88.3% | — | |
| LTM Mar 2026 | $10.36M | — | — | 19.3% | |
| LTM Mar 2026 | $24K | -100.0% | +3.8% | — | |
| Peer median (excluding TENX) | $43.72M | +21200.1% | +13.4% | 77.0% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (32.47M) | (11.05M) | (7.71M) | (17.6M) | (52.6M) |
| Depreciation & Amortization | 108.98K | 113.33K | 8K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 191K | 1.13M | 0 |
| Change in Working Capital | (610.09K) | (1.45M) | 1.58M | 1.64M | (2.36M) |
| Accounts Receivables | (22.5K) | 0 | (306K) | 58K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | (344.95K) | 1.65M | 1.06M | 2.88M |
| Other Working Capital | (587.59K) | (1.1M) | 237K | 523K | (5.25M) |
| Other Non-Cash Items | 22.12M | 366.86K | 25K | 23K | 19.16M |
| Operating Cash Flow | (10.86M) | (12.01M) | (5.9M) | (14.81M) | (35.8M) |
| Capital Expenditures | (5.25K) | (2.33K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (345.54K) | 0 | 0 | 0 | 0 |
| Sales of Investments | 803.4K | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 3K | 0 | 0 |
| Investing Cash Flow | 452.61K | (2.32K) | 3K | 0 | 0 |
| Debt Repayment | 0 | 624.3K | (624K) | (501K) | 0 |
| Common Stock Issued | 9.19M | 7.93M | 14.19M | 100.37M | 38.51M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 544.65K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 9.74M | 8.55M | 13.57M | 99.87M | 38.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (666.32K) | (3.46M) | 7.67M | 85.06M | 2.71M |
| Free Cash Flow | (10.86M) | (12.02M) | (5.9M) | (14.81M) | (35.8M) |
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.